TWiV reviews evidence that symptomatic adenovirus infection leads to thrombocytopenia, thrombosis, and production of anti-platelet factor 4 antibodies similar to the rare disorder seen after immunization with adenoviral vectored COVID-19 vaccines, and a monoclonal antibody isolated from a SARS survivor, following vaccination with a SARS-CoV-2 spike mRNA vaccine, that neutralizes a broad collection of ACE2-binding sarbecoviruses..
From the European Society for Clinical Virology 2022 Conference in Manchester UK, Vincent speaks with Emma Thomson about the recent outbreak of pediatric hepatitis of unknown etiology and the finding that it is linked to infection by adenovirus-associated virus 2.
TWiV explains what is known about cases of acute, severe hepatitis of unknown origin in children, and discovery of an inhibitor of TMPRSS2 protease that blocks SARS-CoV-2 infection.
TWiV reviews the results of serum neutralization assays which show that a third vaccine dose restores neutralization of the Omicron variant, and interaction of platelet factor 4 with the adenovirus capsid, suggesting a mechanism for thrombosis with thrombocytopenia syndrome.
Sociomedical scientist Robert Fullilove joins TWiV to discuss disparities in minority health; FDA announces an EUA on Yale’s SalivaDirect, protection of the upper and respiratory tract of mice after intranasal inoculation with an adenovirus-vectored SARS-CoV-2 spike gene, and listener questions.
TWiV reviews a new H1N1 swine influenza virus from China with pandemic potential, Ad5 vectored SARS-CoV-2 oral vaccine candidate, Operation Warp Speed vaccine candidates, FDA guidance on vaccine approval, and answer listener email.
The TWiV team reveals the repertoire of anti-viral antibodies in newborn humans, and a complement protein that binds the adenovirus capsid and prevents release of the viral DNA.
Vincent travels to Microbiotix, Inc, a biopharmaceutical company in Worcester, MA to speak with four members of the company about their discovery and development of small molecule drugs that target serious infectious diseases.
At the University of Zürich, Vincent speaks with virologists Cornel Fraeful, Urs Greber, and Silke Stertz about their careers and their work on AAV2, adenovirus entry, and influenza virus.
The TWiVome reveal the first eukaryotic genes in a bacteriophage of Wolbachia, and how DNA tumor virus oncogenes antagonize sensing of cytoplasmic DNA by the cell.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Jolene Ramsey, Ph.D.